IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-23. Numbers and descriptions here follow the published literature rather than marketing material.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Requires reconstitution before use |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Storage, powder | 2 to 8 degrees Celsius | Protect from light and moisture |
| Storage, solution | Refrigerated, short term | Use promptly after reconstitution |
| Common assays | Reversed-phase HPLC and mass spectrometry | Purity and identity respectively |
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
== Types == All human rabies vaccines are inactivated vaccines made by inactivation of virus-containing material. The oldest kind are nerve tissue vaccines, made from the nerve tissue of rabies-infected animals. They are still approved in a few countries. They are not recommended by the WHO as they are less effective and have greater side effects. They also contain impurities of nervous origin such as myelin. Instead, WHO recommends Cell Culture Vaccines and Embryonated egg-based vaccines (CCEEV), where the virus is grown in cultured cells or fertilized duck eggs before being inactivated. The virus is then separated out and used for making the vaccine by ultrafiltration or ultracentrifugation. The process renders CCEEVs purer and more concentrated, which contributes to its safety and effectiveness. As with the older type, CCEEVs can be used in both pre- and post-exposure vaccinations. Specific CCEEVs are classified by the type of cell the virus is grown in and include:
In the ensuing power struggle for control over the province, General Wang Zuanxu made a deal with Liu that he would return the Ya'an and Xichang regions to Xikang as well as subsidize the Xikang government with 360,000 yuan per year in exchange for Liu's support. This deal went through, and the central government even agreed to fund a highway from Sichuan to Xikang. On 28 November, 1938, the Executive Yuan ratified the establishment of Xikang Province, which was officially inaugurated on 1 January, 1939. Liu Wenhui became the governor of Xikang. In exchange, Wang Zuanxu was able to become the acting chairman of Sichuan Province, although he failed to secure control and was later usurped by Chiang Kai-shek himself. Liu Wenhui's provincial government was highly nepotistic, made up mostly of personal connections, secretaries, and subordinate officers. Only one politician in the new government, Ye Xiufeng, was a Chiang loyalist: he was subsequently outmaneuvered by Liu and dismissed within two years. Although the Tibetan population were hopeful that the establishment of the province would entail increased representation, Liu only appointed one Tibetan, a monk, to the governing board. This was justified by the national government as a prioritization of national stability over minority rights, ensuring that the Xikang government remained Han-centric and Han-dominant. In addition, the wartime situation meant that by cooperating with the central government, Liu Wenhui would be able to maintain his rule over Xikang.
==== Statistical power ==== In any clinical trial, the number of subjects, also called the sample size, has a large impact on the ability to reliably detect and measure the effects of the intervention. This ability is described as its "power", which must be calculated before initiating a study to figure out if the study is worth its costs. In general, a larger sample size increases the statistical power, also the cost. The statistical power estimates the ability of a trial to detect a difference of a particular size (or larger) between the treatment and control groups. For example, a trial of a lipid-lowering drug versus placebo with 100 patients in each group might have a power of 0.90 to detect a difference between placebo and trial groups receiving dosage of 10 mg/dL or more, but only 0.70 to detect a difference of 6 mg/dL.
== Metabolism == Dihydrocodeine is metabolised by the CYP450 system isoenzyme 2D6 to dihydromorphine, which mediates the majority of its analgesic effects. Owing to the low oral bioavailibility of dihydrocodeine (20%), and its subsequent metabolism to active compounds, it is likely that doses below 30mg are sub therapeutic for analgesia.
Compounding the concerns over massive pre-orders by wealthy countries, manufacturing capacity is also limited by the fact that most vaccines are patented by companies in those countries. India and South Africa proposed a waiver to the TRIPS Agreement which would remove exclusivity agreements as a barrier to setting up new facilities but the measure is being blocked by the G7.
Sources: en.wikipedia.org
Typically, the higher the temperature the kiln operates at, the larger amount of emissions are produced (per pound of water removed). This is especially true in the drying of thin veneers and high-temperature drying of softwoods.
Other companies he founded include Maxygen (1997), a developer of technologies that improve the development of proteins and genetic elements, and SurroMed, focusing on the development of technologies for surrogate disease markers. In 2000, he founded Alexza Pharmaceuticals, a company working on rapid onset of action drug delivery technologies. He died at his home at Atherton, California, on March 1, 2014 from complications of dementia. He was 91.
=== Origins and development (2023–2025) === The Enhanced Games (TEG) is to be the first event of its kind to support performance-enhancing drugs and not follow the rules of the World Anti-Doping Agency (WADA). Performance-enhancing drugs will not be mandatory for participants. When announced in June 2023, the event was intended to be annual and to include five categories: track and field, swimming, weightlifting, gymnastics, and combat sports. Such an event has been discussed hypothetically for many years but never been realised. Prosthetic limbs and shoe technology will be allowed. Aron D'Souza, president of the organisation, says that for insurance reasons, only FDA-approved substances will be allowed. Cocaine and heroin will not be allowed. According to D'Souza, athletes should also be categorised based on their chromosomal sex. Originally planned for December 2024, D'Souza estimated the number of athletes to be "maybe a couple of thousand". By late 2025, organizers were aiming for 50 participants in the first event, with 38 confirmed as of 10 February 2026. Brett Fraser, chief athletics officer of the organisation, said that the planned included sports are a "core suite of products", and can be improved upon in the future. The scale will depend on funding, and the location was planned to be a university campus or similar facility in the southern United States. D'Souza said in early 2024 that he now had the equity capital to fund the first event.
== Incidence == Unfortunately, there is no absolute definition that describes the incidence of drug-induced QT prolongation, as most data is obtained from case reports or small observational studies. Although QT interval prolongation is one of the most common reasons for drug withdrawal from the market, the overall incidence of drug-induced QT prolongation is difficult to estimate. One study in France estimated that between 5-7% of reports of ventricular tachycardia, ventricular fibrillation, or sudden cardiac death were in fact due to drug-induced QT prolongation and torsades de pointes. An observational study from the Netherlands showed that 3.1% of patients who experienced sudden cardiac death were also using a QT-prolonging drug.
== Constantly evolving == Since its initial implementation in the early 2000s, the freely available METLIN website has collected comments and suggestions for improvements from users in the biotechnology, pharmaceutical and academic communities ultimately resulting in functionally useful technology for metabolomics as well as hundreds of thousands of other molecular entities. The METLIN interface allows researchers to readily search the database and characterize metabolites and other compounds through features such as accurate mass, single and multiple fragment searching, neutral loss and full spectrum search capabilities. The similarity searching feature introduced in 2008 was designed to expedite the identification process of unknown molecules. Also, METLIN has been used to create a novel multiple reaction monitoring (MRM) library of precursor to fragment ion transitions. The METLIN-MRM transition repository for small-molecule quantitative tandem mass spectrometry was designed to facilitate data sharing across different instruments and laboratories. A new version of generating MRM transitions was introduced in 2026 as uMRM [1], and takes advantage of the original METLIN-MRM concepts. uMRM however is designed to remove isotopes and in-source fragments (ISF) prior to generating MRMs using a spline-fitting method using multiple collision energies. The METLIN database is implemented in the cloud to enable users throughout the world.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.
Mass spectrometry gives the observed mass, which is compared against the value calculated from the sequence. Peptide mapping after digestion provides a second, sequence-level check. Chromatographic retention alone is not sufficient for identity.
Antibodies raised against one GHRH-related peptide may bind other members of the same family. That cross-reactivity inflates or distorts measured concentrations. Assay validation with defined standards is therefore necessary before results are interpreted.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.